Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refractory celiac disease.

Hani Abdallah1, Daniel Leffler, Melinda Dennis

  • 1The Celiac Center, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.

Current Gastroenterology Reports
|November 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digestion supplemented with commercial proteases: Evaluation of the fate of gluten immunogenic peptides in pizza.

Food research international (Ottawa, Ont.)·2025
Same author

Prevalence of Serologically Defined Celiac Disease in Patients With Irritable Bowel Syndrome in Asia: A Multicountry Hospital-Based Study.

Journal of gastroenterology and hepatology·2025
Same author

Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions in <i>C. difficile</i> infection (CDI), asymptomatic carriage and non-CDI diarrhea.

Gut microbes·2025
Same author

Hereditary Alpha-Tryptasemia Is Associated With Ongoing Symptoms in Individuals With Celiac Disease Despite Following a Gluten-free Diet.

The American journal of gastroenterology·2025
Same author

Comparative effectiveness of metronidazole and vancomycin for treatment of <i>Clostridioides difficile</i> infection in hospitalized children.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025
Same author

Dietary assessments in individuals living with coeliac disease: key considerations.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2024
Same journal

Management of Common Bile Duct Stones: Current Approaches and Evolving Endoscopic Strategies.

Current gastroenterology reports·2026
Same journal

Solitary Rectal Ulcer Syndrome Revisited: A Comprehensive Narrative Review.

Current gastroenterology reports·2026
Same journal

The Microbiome and Esophageal Disease: Where Are We Now?

Current gastroenterology reports·2026
Same journal

Fermented Durian Tempoyak as a Source of Probiotics for Colorectal Cancer Prevention through Gut Microbiome Modulation.

Current gastroenterology reports·2026
Same journal

A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.

Current gastroenterology reports·2026
Same journal

The Role of Endoscopic Ultrasound in the Diagnosis and Management of Congenital Gastrointestinal and Pancreaticobiliary Conditions.

Current gastroenterology reports·2026
See all related articles

Refractory celiac disease (RCD) occurs when celiac disease symptoms persist despite a gluten-free diet. RCD requires careful evaluation to differentiate between types I and II, impacting prognosis and treatment.

Area of Science:

  • Gastroenterology
  • Immunology
  • Internal Medicine

Background:

  • Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals (HLA-DQ2/DQ8).
  • Nonresponsive CD (NRCD) is diagnosed when CD symptoms persist despite a strict gluten-free diet (GFD) for over six months.
  • Refractory CD (RCD) is a severe form of NRCD characterized by persistent villous atrophy on biopsy despite a strict GFD.

Purpose of the Study:

  • To define Refractory Celiac Disease (RCD) as a cause of Nonresponsive CD (NRCD).
  • To outline diagnostic considerations for RCD, distinguishing it from other NRCD causes.
  • To categorize RCD into types I and II, detailing their distinct prognoses and management strategies.

Main Methods:

  • Literature review and clinical case analysis of patients with persistent CD symptoms despite GFD adherence.

Related Experiment Videos

  • Diagnostic criteria for RCD, emphasizing villous atrophy on small intestinal biopsy.
  • Classification of RCD into Type I and Type II based on clinical presentation and prognosis.

    • Main Results:

    • RCD is a rare but critical diagnosis in patients with persistent CD symptoms and villous atrophy.
    • Type I RCD generally has a better prognosis and may respond to nutritional support and mild immunosuppression.
    • Type II RCD carries a poor prognosis, with risks of malnutrition and progression to T-cell lymphoma, managed with immunosuppression or stem cell transplant.

    Conclusions:

    • RCD necessitates a thorough diagnostic workup to differentiate it from other causes of NRCD.
    • The distinction between Type I and Type II RCD is crucial for guiding appropriate patient management and predicting outcomes.
    • While Type I RCD is manageable, Type II RCD presents significant therapeutic challenges and a guarded prognosis.